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Abstract
Background: The Gambia Hepatitis Intervention Study (GHIS) was designed as a randomised control trial of infant
hepatitis B vaccination applied to public health policy, with the main goal of preventing primary liver cancer later in
adult life in The Gambia. To that effect, the National Cancer Registry of The Gambia (NCR), a population-based
cancer registry (PBCR), was established in 1986 to actively collect data on all cancer diagnosis nation-wide. We
extracted 20-years (1990-2009) of data to assess for the first time, the evolution of the most common cancers, also
describe and demonstrate the role of the PBCR in a hepatitis B and liver cancer prevention programme in this
population.
Methods and Findings: We estimated Age-Standardised Incidence Rates (ASR (W)) of the most common cancers
registered during the period by gender. The registration period was divided into four 5-year intervals and incidence
rates were estimated for each interval. The most common cancers in males were liver, prostate, lung plus bronchus,
non-Hodgkin lymphoma (NHL) and stomach, accounting for 60%, 5%, 4%, 5% and 3%, respectively. Similarly,
cancers of the cervix uteri, liver, breast and NHL, were the most common in females, accounting for 33%, 24%, 11%
and 4% of the female cancers, respectively.
Conclusions: Cancer incidence has remained relatively stable over time, but as shown elsewhere in sub-Saharan
Africa the disease is a threat in The Gambia. The infection related cancers which are mostly preventable (HBV in
men and HPV/HIV in women) were the most common. At the moment the data is not enough to detect an effect of
hepatitis B vaccination on liver cancer incidence in The Gambia. However, we observed that monitoring case
occurrence through PBCR is a key public health pre-requisite for rational planning and implementation of targeted
interventions for improving the health of the population.
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Introduction
While the advent of the Acquired Immuno-Deficiency
Syndrome (AIDS) contributed to renewed interest in AIDS-
related or infection-related cancers and possible co-factors,
there is still limited knowledge about cancer incidence and its
evolution in relation to the rapid demographic and lifestyle
changes in sub-Saharan Africa. The main reasons for this lack
of knowledge are mainly due to the limited availability and
access to programmes for cancer prevention, early diagnosis
and treatment and the scarcity of population-based cancer
registries with long periods of operation. Nevertheless,
estimates of cancer occurrence suggest that cancer is a major
public health concern in Africa and thus the need for
development and implementation of rational cancer control
programmes to curb the disease and its related effects. The
undisputed basic and or expanded role that the PBCR can offer
in such instances is well known [1-5].
Current literature show variations in the occurrence of cancer
in sub-Saharan Africa and with the advent of the Human
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Immuno-deficiency Virus (HIV) infection and or AIDS pandemic
the emergence of a new cancer pattern is eminent [6,7].
Currently in West Africa the most common cancers in men are
liver and prostate and in women cervix and breast cancers
[8-11]. In East and South of the continent, Kaposi sarcoma has
now over shadowed the occurrence of oesophagus, cervix and
liver cancer by emerging as the most common malignancy in
both sexes in recent reports [6,12-14]. The continuous
monitoring and evaluation of such information can provide for
effective health planning and policy for cancer control in sub-
Saharan Africa. This echoes the importance of establishing
more population-based cancer registries in sub-Saharan Africa.
In fact many reasons have been put forward to show why it is
more of a necessity than a luxury to do so in developing
countries [15].
The National Cancer Registry of The Gambia (NCR) was
established in July 1986. Its main purpose is to provide for the
final evaluation of The Gambia Hepatitis Intervention Study
(GHIS) project. This desired role is being performed in
conjunction with the basic role of a Population-Based-Cancer-
Registry (PBCR) [16]. To our knowledge it is currently the only
PBCR in sub-Saharan Africa that achieved nation-wide
coverage including coverage of a substantial indigenous rural
population. The main goal of the GHIS project is to evaluate
the protective effectiveness of infant immunisation against
chronic Hepatitis B Virus (HBV) infection in the prevention of
chronic liver disease, specifically, primary liver cancer and
cirrhosis later in adult life [17]. In principle therefore, the role of
the NCR is more consistent with an expanded role as
described for a PBCR (see reference [1]), than the basic role
assumed by similar institutions in the context of sub-Saharan
Africa [9,10,13,18-21]. Fulfilment of its basic role as a PBCR in
the context of sub-Saharan Africa is evident from examination
of its previous reports. These reports describe incidence of
cancer during the period July 1986 – June 1988 [22],
1988-1997 [8] and an increase in female liver cancer with
ethnic variations in the occurrence of cervix and breast cancer
have been described recently [23]. In this study we utilised
twenty years of data (1990-2009), to further characterise the
baseline cancer incidence information collected as part of the
GHIS project with an attempt to map out and demonstrate both
the basic and expanded role assumed by the cancer registry,
i.e. a PBCR in the context of hepatitis B and liver cancer
control in sub-Saharan Africa.
Methods
Cancer records
The method of data collection and the problems encountered
as well as the procedures of the cancer registry were described
in previous reports [8,22]. Notification of cancer is voluntary in
The Gambia and cancer registration is an active process.
Trained cancer registry staff visits all health institutions, both
public and private, engage clinicians to contribute to the
register and scan the identified data sources for cancer
diagnoses. Initially, the cancer registry operated from one base
office, actively collecting data throughout the country. In
1997-1998, a decentralization process was developed to better
integrate the operations of the cancer registry with the medical
services. Trained cancer registration field staff were posted at
the major tertiary care facilities, namely, Edward Francis Small
Teaching Hospital (EFSTH) in Banjul, (formerly, Royal Victoria
Teaching Hospital), Medical Research Council in Fajara,
Armed Forces Provisional Ruling Council General Hospital in
Farafenni and Bansang Hospital in Bansang, with responsibility
to collect data on all cancer diagnoses within a specified
geographical area of the country. The registry staff is also
active in the co-ordination of an ultrasound examination
service, channelling cytology and biopsy specimens to the only
histopathology laboratory service based at the EFSTH, storing
and managing the clinical files of cancer patients, and
collecting blood and performing laboratory tests. Specifically,
quantitation of alpha-fetoprotein and hepatitis B surface antigen
(HbsAg) in plasma to assist clinical diagnosis of chronic liver
disease mainly, primary liver cancer.
This study was conducted in The Gambia as part of the
GHIS project which was approved by the Joint Gambia
Government (GG) /Medical Research Council (MRC) Ethics
committee. The study was endorsed by the local steering
committee of the GHIS project. In line with most places
elsewhere in the world, obtaining patient consent for inclusion
of personal and tumour details, encrypted in the cancer registry
database, was not required by any of the committees
mentioned above.
The NCR database was automated from inception and is
managed using the CANREG system [24] since the early ‘90s.
It collects personal information including names, usual
residence, age, sex, ethnic and civil status as well as details on
the tumour including primary site, morphology, basis and date
of diagnosis and hospital/clinic of initial diagnosis and
registration. All patients diagnosed by a medically qualified
doctor are eligible for inclusion into the database. Tumour site
and morphology are coded according to the International
Classification of Diseases for Oncology, third edition (ICDO-3)
[25].
Population data
Decennial population censuses have been performed in The
Gambia since 1901. The population of The Gambia grew from
687,817 in 1983 to 1.4 million in 2003 (the latest officially
published population census at the time of this analysis). Life
expectancy at birth have also increased both in males and
females to over 60 years in recent years [26]. In order to
compute incidence rates and their 95% confidence intervals,
we estimated the population at risk for each of the periods
under review, using standard formula of population
interpolation and extrapolation of the census figures of 1983,
1993 and 2003. Such that for period 1 and 2 the figures were
interpolated using the census figures of 1983 and 1993, while
the figures of period 3 and 4 where extrapolated using the 2003
census. Figure 1 shows the population pyramid of The Gambia
for the period under review.
Statistical methods
In this analysis we grouped data collected over a 20-year
period, 1990-2009, into four by 5-year strata, namely,
Population-Based Cancer Registration in The Gambia
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1990-1994, 1995-1999, 2000-2004 and 2005-2009 (denoted as
period 1, 2, 3 and 4, respectively in the text). For each of the
four by 5-year periods and for the whole period under review
and by five-year age groups, we computed the relative
frequency (%) and crude incidence rates. The rates were
adjusted for age using the world standard population [27]
commonly utilised in the comparison of cancer registry
information from different parts of the globe (see references
[7,28]). Similarly, we calculated the corresponding 95%
confidence intervals (95%CI) for each age-adjusted rate
(ASR(W)) using the standard statistical formula described by
Boyle & Parkin [29]. Differences in incidence between periods
were tested using the Maentel-Haenzel method with
modifications using the standard statistical formula described
by Esteve and colleagues [30].
Results
Over the 20-year period, i.e. 1990-2009, a total of 7,991
malignant tumours were registered among usual residents of
The Gambia, 52% males and 48% females. In Tables 1 and 2,
the number, relative frequency (%), ASR (W) with its
corresponding 95%CI by primary cancer site and period, are
shown for males and females, respectively. We show similar
statistics in Table 3 for all cancer registrations by period and
sex.
In males, the most common cancers in each of the periods
examined were liver, comprising 60% of all cancers, prostate
(5%), lung and bronchus (4%), Non-Hodgkin Lymphoma (NHL)
(5%) and stomach (3%). There was no significant increase in
the evolution of incidence of any of the most common sites
studied in males except for prostate cancer, which showed a
doubling in incidence during period 4 compared to period 1. We
did not observe any clear trend in the overall cancer incidence
rates in females during the period examined here. Our analysis
revealed that the most common cancers among female
Gambians are cervix uteri which accounted for 33% of cancers
in this group followed by liver cancer (24%), breast cancer
(11%) and NHL (4%). Also, beside cervical cancer, the
incidence rates of most major cancers shown in Table 1 and
Table 2 for males and females respectively are comparable to
those reported in a recent review of cancer incidence rates in
West Africa [11]
Histological diagnosis
Data quality, as may be judged from confirmation of clinical
diagnosis of cases via histology and or cytology, has improved
across the four periods which were examined in this analysis.
Table 4 show the percentage of morphological verification of
clinical diagnosis of cancer in The Gambia by site and period;
and to show further details of this information, the percentage
of the most common histological diagnosis by site were also
provided (see Table 5). Overall, more than 20% of all cancer
cases are now confirmed by histology in The Gambia and
excluding liver, this figure reaches beyond 40%. Clinical
diagnosis of liver cancer was less confirmed by histology,
below 5% of cases after year 2000, coinciding with the period
when recruitment of liver cancer cases for the second case-
Figure 1.  Estimated population at risk by age group and sex: The Gambia, 1990-2009.  
doi: 10.1371/journal.pone.0075775.g001
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control study in The Gambia [31] was concluded. Indeed, the
late presentation of liver cancer patients to hospital and the
absence of treatment options after diagnosis make it medically
and ethically not justified to carry out routine biopsies on these
patients. This situation may change with the recent revival and
expansion of the liver disease referral clinics in-country. The
service is now run by two resident consultant Hepatologists
involved with the GHIS project and an ancillary international
research project in West Africa on treatment of chronic HBV
infection in adults above age 29.
Liver cancer
Figures 2 and 3 show the age-specific incidence curves of
liver cancer by period in males and females, respectively. In
each of the sexes, the peak of incidence shows a complex
progressive advancement by age and period. Notably, there is
a rapid rise in incidence rates in young male Gambians during
Table 1. Number of cases, ASR per 100,000 person-years
with 95% Confidence Intervals of the most common
cancers by primary site and period and all cancer
registrations by period - Males: The Gambia, 1990-2009.
 PRIMARY SITE OF CANCER (ICD-10)   
PERIOD Liver (C22)
Prostate
(C61)
Lung+
Bronchus
(C33-C34)
NHL (C82-
C85)
Stomach
(C16)
1990-1994      
No. of
cases*(%) 467 (61) 21 (3) 33 (4) 42 (5) 23 (3)
**ASR
(95%CIs)
29.0
(26.2-31.7)
1.7
(1.0-2.4)
2.5
(1.6-3.3)
2.0
(1.4-2.7)
1.5
(0.9-2.1)
1995-1999      
No. of
cases*(%) 551 (55) 43 (4) 43 (4) 56 (6) 26 (3)
**ASR
(95%CIs)
30.3
(27.7-33.0)
3.0
(2.1-4.0)
2.9
(2.0-3.8)
2.3
(1.6-3.0)
1.6
(1.0-2.3)
2000-2004      
No. of
cases*(%) 659 (61) 44 (4) 45 (4) 48 (4) 24 (2)
**ASR
(95%CIs)
31.4
(28.9-33.9)
2.9
(2.0-3.7)
2.7
(1.9-3.5)
1.4
(0.9-1.8)
1.3
(0.8-1.9)
2005-2009      
No. of
cases*(%) 809 (62) 85 (7) 37 (3) 68 (5) 37 (3)
**ASR
(95%CIs)
34.7
(32.1-37.2)
4.9
(3.8-5.9)
2.1
(1.4-2.8)
2.0
(1.5-2.5)
2.0
(1.3-2.6)
Total
(1990-2009)      
No. of
cases*(%) 2,486 (60) 193 (5) 158 (4) 214 (5) 110 (3)
**ASR
(95%CIs)
31.6
(30.3-32.9)
3.2
(2.8-3.7)
2.5
(2.1-2.9)
%1.1
(1.6-2.2)
1.6
(1.3-1.9)
* (%) = Percentage of total cases in period; ** ASR = Age-standardized incidence
rate per 100,000 person-years (Standardized to the World Standard population).
doi: 10.1371/journal.pone.0075775.t001
all periods. This is followed by a display of incidence peaks
after age 50 and a nadir in incidence observed in the oldest
generation (i.e. beyond age 60). In contrast to female
Gambians, a less dramatic rise in incidence rates in young
ages is observed. A striking observation in recent times in
females, is the shift in peak incidence from age group 50 in
period 2 to age group 55 in period 3, followed by a continuous
rise in incidence rates into the older ages during period 4. The
shape of the incidence curve in period 4 is in contrast to the
familiar pattern of a nadir in incidence in the oldest age range
observed in these series from The Gambia. This observation
may be suggesting improved case ascertainment in the NCR
and or depicting a cohort effect in the older female generation,
specifically above age 50. An earlier analysis of the NCR data
covering the period 1988-2006 found the recent rise in female
liver cancers in The Gambia to be statistically significant with a
percentage change of 3.01 (95% CI [0.3-5.8]) [32].
Cervical cancer
In females, cervical cancer was the most common cancer
across all periods. There is evidence of an increase in the
diagnosis of the disease after period 1 and consequently,
period 2 exhibits the highest incidence rate with ASR (W) at
20.1 per, 100,000 person-years. In period 4, the ASR (W) was
Table 2. Number of cases, ASR per 100,000 person-years
with 95% Confidence Intervals of the most common
cancers by primary site and period and all cancer
registrations by period - Females: The Gambia, 1990-2009.
 PRIMARY SITE OF CANCER (ICD-10)  
PERIOD
Cervix uteri
(C53) Liver (C22) Breast (C50)
NHL (C82-
C85)
1990-1994     
No. of cases*(%) 199 (31) 138 (21) 67 (10) 25 (4)
**ASR (95%CIs) 13.9 (11.8-16.0) 9.6 (7.9-11.3) 5.0 (3.7-6.2) 1.2 (0.7-1.7)
1995-1999     
No. of cases*(%) 361 (34) 205 (20) 100 (10) 36 (3)
**ASR (95%CIs) 20.2 (17.9-22.4) 13.1(11.2-15.1) 5.8 (4.6-7.0) 1.4 (0.8-1.9)
2000-2004     
No. of cases*(%) 276 (30) 245 (26) 113 (12) 46 (5)
**ASR (95%CIs) 13.7 (11.9-15.4) 12.2(10.5-13.9) 5.5 (4.4-6.6) 1.6 (1.0-2.2)
2005-2009     
No. of cases*(%) 418 (34) 337 (28) 156 (13) 39 (3)
**ASR (95%CIs) 19.1 (17.2-21.1) 15.0(13.3-16.8) 6.7 (5.5-7.8) 1.6 (1.0-2.1)
Total
(1990-2009)     
No. of cases*(%) 1,254 (33) 925 (24) 436 (11) 146 (4)
**ASR (95%CIs) 16.9 (15.9-17.9) 12.8(11.9-13.7) 5.8 (5.2-6.4) 1.5 (1.2-1.7)
* (%) = Percentage of total cases in period; ** ASR = Age-standardized incidence
rate per 100,000 person-years (Standardized to the World Standard population).
doi: 10.1371/journal.pone.0075775.t002
Population-Based Cancer Registration in The Gambia
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19.1 per 100,000 person-years. Figure 4 shows the age
specific incidence curves by period. The rates show a steep
rise in the youngest age groups and in addition a bi-modal
pattern of occurrence after age 35. Although the incidence
rates during the 1995-1999 period were by far the highest, the
Table 3. Number of cases, ASR per 100,000 person-years
with 95% Confidence Intervals of the most common
cancers by primary site and period and all cancer
registrations by period - All cancer registrations: The
Gambia, 1990-2009.
PERIOD Males Females
1990-1994   
No. of cases*(%) 771 (100) 649 (100)
**ASR (95%CIs) 47.8 (44.3-51.4) 44.7 (40.9-48.4)
1995-1999   
No. of cases*(%) 994 (100) 1,049 (100)
**ASR (95%CIs) 55.1 (51.5-58.7) 61.2 (57.2-65.3)
2000-2004   
No. of cases*(%) 1,072 (100) 930 (100)
**ASR (95%CIs) 51.3 (48.8-54.5) 45.4 (42.2-48.5)
2005-2009   
No. of cases*(%) 1,305 (100) 1,221 (100)
**ASR (95%CIs) 57.5 (54.2-60.8) 54.8 (51.5-58.1)
Total (1990-2009)   
No. of cases*(%) 4,142 (100) 3,849 (100)
**ASR (95%CIs) 53.3 (51.6-55.0) 51.8 (50.0-53.6)
* (%)=Percentage of total cases in period; ** ASR = Age-standardized incidence
rate per 100,000 person-years (Standardized to the World Standard population).
doi: 10.1371/journal.pone.0075775.t003
Table 4. Percentage (of total in period) of cancers
morphology verified (MV %) by period and by site.
   PERIOD   
PRIMARY
SITE OF
CANCER
(ICD-10
code)
1990-1994 1995-1999 2000-2004 2005-2009 1990-2009
Liver (C22) 5.0 3.8 4.1 0.9 3.1
Prostate
(C61) 19.0 30.2 20.5 30.6 26.9
Lung +
Bronchus
(C33-C34)
18.4 10.0 9.8 16.7 13.4
NHL (C82-
C85) 37.3 48.9 48.9 61.7 50.6
Stomach
(C16) 8.7 28.6 18.2 46.8 26.2
Cervix (C53) 14.1 26.9 23.6 23.7 23.0
Breast (C50) 39.7 48.1 65.3 63.8 56.9
All sites 16.7 24.5 23.9 24.1 22.8
doi: 10.1371/journal.pone.0075775.t004
shape of the incidence curve shares similar features with those
of the periods which follow.
Prostate, lung plus bronchus, stomach, breast and NHL
cancers
The incidence curves of prostate, male lung plus bronchus
cancers, male stomach cancers, female breast cancers and
NHL in males and females are shown in Figure 5 for the period
1990-2009. During this 20-year period, in terms of the
ASR(W)s, prostate, lung plus bronchus, NHL and stomach
cancers were the second, third, fourth and fifth most common
cancers in males. In females, breast and NHL were the third
and fourth most common cancers during the period. A gradual
increase in breast cancer incidence rates in young women
reaching a peak at age 45 and exhibiting a second peak at age
55 followed by a sudden decline afterwards is shown in Figure
5. Such sharp decline in incidence rates mirrors the familiar
phenomenon of under ascertainment incurred in the NCR
which is particularly observed in the older age categories of this
population. Furthermore, Figure 5 shows that female breast
cancer is the most important cancer before age 55 and is
exceeded only by prostate cancer after that age when it sharply
declines in incidence. There is no breast cancer screening in
The Gambia. The recent introduction of Prostate Specific
Antigen (PSA) testing in The Gambia may have been
responsible for the sharp upward turn of prostate cancer
incidence after age 55 which continues to rise into older ages
as expected, making it the most important cancer than lung
plus bronchus and stomach cancers after age 50 in males.
Although a doubling in the incidence rates of prostate cancer
was observed during recent times in The Gambia (see Table 1)
its occurrence is still dwarfed by the incidence rates reported
elsewhere in West Africa [7].
NHL is the fourth most common cancer in male and female
Gambians with Burkitt lymphoma (BL) being the most common
Table 5. Percentage (%) of the most common morphology
diagnosis by primary site: The Gambia, 1990-2009.
PRIMARY SITE OF
CANCER (ICD-10
code)
MOST COMMON MORPHOLOGY (ICD-
O-3 code) % (NUMBERS)
Liver (C22) Hepatocellular carcinoma, NOS (8170) 82.1% (87/106)
Prostate (C61) Small cell carcinoma, NOS (8041) 69.2% (36/52)
Lung + Bronchus
(C33-C34) Small cell carcinoma, NOS (8041) 12.0% (3/25)
 Squamous cell carcinoma, NOS (8070) 24.0% (6/25)
 Adenocarcinoma, NOS (8140) 12.0% (3/25)
NHL (C82-C85) Malignant lymphoma, NOS (9590) 32.4% (59/182)
 Malignant lymphoma, non-Hodgkin,NOS (9591) 29.1% (53/182)
 Burkitt lymphoma, NOS (9687) 20.3% (37/182)
Stomach (C16) Adenocarcinoma, NOS (8140) 50.0% (22/44)
Cervix (C53) Squamous cell carcinoma, NOS (8070) 51.9% (150/289)
Breast (C50) Infiltrating duct carcinoma, NOS (8500) 57.4% (147/256)
doi: 10.1371/journal.pone.0075775.t005
Population-Based Cancer Registration in The Gambia
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morphological type in both sexes. In 1990-2009, 37 male BL
cases (17% of male NHL cases) and 35 female BL cases (24%
of female NHL cases) were registered. Majority of these cases,
92% and 87%, occurred below age 15 in males and females,
respectively. Below age 15 NHL appears to exhibit a similar
pattern of occurrence in both sexes with rates being higher in
males than in females. However afterwards, especially in the
older ages, a variable pattern in incidence curves is revealed
with the females exhibiting a much higher incidence. Such that
in females higher rates are observed after age 45 with a peak
at age 55 and lower rates for women with age over 55. In
males, the higher rates were observed from age 25 with peaks
at age groups 30, 40 and 60 followed by lower rates at ages
higher than 60. The difference and the various peaks in
incidence rates observed in the older ages may be due an
artefact of the small number of cases available to us in this
analysis, again as a result of the under ascertainment observed
in the older generation of this population [22].
Discussion
Overall our analysis shows that the occurrence of the most
common cancers in both sexes was relatively stable over time
in The Gambia, with the exception of liver cancer in females
and prostate cancer. Our assessment of cancer incidence
further strengthens the evidence implicating the infection-
related cancers of liver and cervix as the most important
cancers in The Gambia. The potential impact of the current
policy of immunisation of infants against hepatitis B infection on
primary liver cancer incidence in The Gambia cannot be
detected at this point in time. More data need to be collected
overtime via the PBCR for that to be achieved by 2017-2020
(see reference [33]).
Previous analysis showed primary liver cancer as the most
common cancer affecting male Gambians [8,22]. In this
analysis the disease continues to be the leading cancer site
across all periods in males (constituting 60% of all cancer
cases in males) and in females it is the second most common
cancer after cervix (constituting 24% of all cancer cases in
females). While the age-standardised incidence rates suggest
the disease is stable in male Gambians, in their female
counterparts an increase was observed during recent years.
Examination of the male: female ratios of liver cancer observed
in The Gambia further elucidate this evidence. Specifically, the
male: female ratios were 3:1 during the early 90s (i.e. period 1)
stabilising at 2:1 during recent times, confirming the results of
an earlier study (see reference [23]).
Case ascertainment in older ages was among the major
concerns of cancer registration in the country from inception
[22], but our recent analysis shows evidence suggesting
improvements in case ascertainment, although mainly for liver
cancer among the elderly population. Specifically, liver cancer
Figure 2.  Age-specific incidence rates of liver cancer by period in male Gambians.  
doi: 10.1371/journal.pone.0075775.g002
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in females has increased during the most recent period
exhibiting an increased incidence rate into the older ages which
is in contrast to the patterns observed in earlier periods. Also,
the peak age of incidence of liver cancer by period, have
shifted progressively more into the older ages in both sexes
particularly in Gambian females. In females, the shift increased
with age and period i.e. from age 55 in period 2 to above age
60 during recent times.
However, it is also possible that factors other than
improvements in case ascertainment could be responsible for
the increase observed in female liver cancer. These include
factors associated with major lifestyle changes and viral
factors, specifically, obesity and hepatitis C virus infection as
described in an earlier review (see reference [23]). Moreover, it
is now known that although the association between HBV
infection and liver cancer is strongest below age 50 in The
Gambia [34], above age 50, HCV infection is more common
and contributes about 20% of HCC cases, particularly in the
female population [31]. Thus, it follows that with the increase in
life expectancy and improved completeness of cancer
registration of the older generations, it is most probable that a
growing number of female liver cancers will continue to be
detected. This warrants a specific control strategy which
includes screening for and treatment of HCV and HBV chronic
infections to complement the current vaccination strategy
against HBV. Such an approach may probably have greater
impact on the occurrence of liver cancer in Gambian women.
Currently, there is no public health policy for the screening and
treatment of HBV and HCV chronic infections in The Gambia.
Monitoring the final outcome of the GHIS project
GHIS is a long-term project, the final outcome of which will
be evaluated via the national population-based cancer
registration scheme established for the purpose i.e. the NCR.
Details of the GHIS project have been described elsewhere
[17]. The GHIS cohort is being followed-up via the NCR to
identify all cases of hepatitis B-related primary liver cancer.
These cases will be linked to the main GHIS immunisation
database that was created from the beginning of the study. A
probabilistic linkage approach is being developed for the
purpose, in addition to efforts via the project, to specifically
improve on the diagnosis of primary liver cancer in The
Gambia. Currently, more than 90% of liver cancers diagnosed
in-country are based on a positive ultrasound examination and
or alpha-feto-protein test [22]. It has been reported that the use
of ultrasound in combination with alpha-fetoprotein testing has
specificity of above 90% in confirming clinical impression of
liver cancer in the Sahel region [35]. This observation has been
confirmed in a limited study on 36 Gambian patients for whom
biopsies were available [36].
It is possible that our current observation in which liver
cancer remains the most common cancer in male Gambians
(more than half of the total number of registered cases), is due
to the specific efforts being made by the GHIS project for the
detection of the disease in the country as noted above.
Figure 3.  Age-specific incidence rates of liver cancer by period in female Gambians.  
doi: 10.1371/journal.pone.0075775.g003
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However, in contrast to female Gambians such a phenomenon
was not observed. In this analysis, primary liver cancer is the
second most common cancer (24%) after cervix uteri cancer
which accounted for a third of all cancers in female Gambians.
Also evident in our current study is the demonstration of the
level of consistency and robustness of liver cancer registration
over the past two decades by the PBCR as achieved in the
context of the GHIS project. In fact, in a recent study the
evidence of high completeness of liver cancer registration
amongst young Gambian male adults, the key target population
for monitoring the final outcome of the GHIS project, was
reported [37]. In this analysis, we observed a much higher risk
of liver cancer than assumed for the country at the time of
designing the GHIS project (see reference [17]). Such
information has bearing on the long-term monitoring and
evaluation of the final outcome of the GHIS project. Hepatitis B
vaccination was successfully integrated into policy in The
Gambia since February 1990 and has reduced infection rates
in children to below 0.5%. This finding suggests a future
decline in the incidence of Primary Hepatocellular Carcinoma
(PHC) in The Gambia. Therefore, with the proper utilisation of
information provided via the PBCR from now on, it will be
possible to estimate and validate reports on the time to
conclusion of the GHIS project. Current estimates along those
lines, suggest that enough cases of PHC for the institution of
proper analysis for detection of a statistically significant effect
of the intervention (i.e. at the 5% level of statistical significance)
will become available in The Gambia from 2017 [33]. If such an
analysis is accomplished the information provided will be key to
rationale health planning and policy in The Gambia and
elsewhere in sub-Saharan Africa. Ensuring the provision of
such key information is testimony to the expanded role being
fulfilled by the PBCR in The Gambia. Thus, irrespective of the
quality issues listed for the PBCR in The Gambia, specifically
poor ascertainment in the rural areas, older ages as described
earlier (see reference [22]) and during recent times (see
reference [37]), overall the evidence shows that the registry will
indeed serve as an effective tool for the evaluation of the GHIS
strategy and continue to fulfil its expanded role as stated
above.
Monitoring the occurrence of the other common
cancers
To accomplish its basic function as a PBCR in the context of
sub-Saharan Africa the NCR monitors the occurrence of all
other cancers in addition to liver cancer. In this analysis we
Figure 4.  Age-specific incidence rates of cervix cancer by period.  
doi: 10.1371/journal.pone.0075775.g004
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observed that cervical cancer is the most common cancer in
The Gambia after liver cancer in males, constituting 33% of all
cancers in females. This compared to the figures for all Africa
where it accounted for 23% of all cancers in females (see
reference [11]), makes its relative weight of occurrence in The
Gambia much higher than elsewhere in the continent. Over a
period of two decades, we found the incidence of cervix cancer
to vary between 13.7 and 20.2 in The Gambia. Though there is
a risk of under-estimation in The Gambia [8], it should be
considered that the excess of incidence in other countries of
sub-Saharan Africa may be attributable to the higher
prevalence of HIV. The prevalence of HIV infection is still low in
The Gambia, below 2% [38,39]. Indeed HIV-infected
heterosexual women carry a 6-fold risk of developing cervix
cancer than the general population [40]. However it is important
to note that relative risks of AIDS-associated tumours, including
cervical cancer are lower in Africa than those reported in
western countries [41] but it is difficult to say whether this is
attributable to delayed access to antiretroviral and competing
causes of AIDS-related deaths. Nevertheless, in The Gambia
the evidence suggest under-reporting of the disease
particularly among the older women. Close examination of the
incidence rates of cervix uteri suggests better case
ascertainment of the disease below the age of 55 in recent
times. However, under ascertainment cannot be ruled out
above this age group. Elsewhere in sub-Saharan Africa much
higher rates of cervix uteri cancer have been reported [7]. The
rapid decline in incidence rates exhibited in the older age
groups may be responsible for the difference in cervix cancer
incidence observed in The Gambia compared to other low
resource areas of the globe [7]. Also, there is currently no
organised screening or other prevention programme against
cervix cancer in The Gambia that could significantly improve
case ascertainment. Moreover, in The Gambia to what extent
older women seek care for this disease or other common
cancer is not documented. It is possible such patients would
rather choose to die at home than present at hospital with
terminal disease, particularly, in the absence of adequate
palliative care in-country.
Breast cancer was among the top four cancers in Gambian
women being the most important after female liver cancer. In
this analysis we observed that most breast cancer diagnoses
were in pre-menopausal women. This is a key characteristic of
the occurrence of this disease in sub-Saharan Africa and
among women of African origin resident elsewhere in the
developed world [42,43]. Furthermore, the Gambia exhibits
significant ethnic variations in female breast cancer incidence
according to recent analysis [23]. The observation of such
interesting features of cancer incidence in this part of the globe
should warrant the conduct of collaborative analytical studies to
further elucidate the genetic and environmental determinants of
the disease. Such efforts can lead to more effective public
health strategies to combat breast cancer globally.
Figure 5.  Age-specific incidence rates of other common cancers in Gambian Males and Females, 1990-2009.  
doi: 10.1371/journal.pone.0075775.g005
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Prostate cancer occurrence has doubled overtime and
exhibits a sharp increase in incidence after age 50. However,
the incidence of the disease is still very low in The Gambia
compared to elsewhere in West Africa, specifically, in Nigeria
were it has increased in incidence over time to become the
leading cancer in men and forming 11% of all male cancers
[44]. Organised screening has been implicated as the cause of
increases in prostate cancer incidence elsewhere in the
developed countries, especially among African-Americans [45].
The pattern and evolution of prostate cancer incidence due to
the effects of introduction of screening organised or
opportunistic, and improved cancer registration, remains to be
elucidated in low resourced countries. In The Gambia, the
increase seen in prostate cancer may be due to an artefact,
specifically, improvement in case ascertainment in the PBCR
as a result of the recent availability and increased utilisation of
serum prostate-specific antigen (PSA) testing in the country.
It is interesting to note that apart from cervix uteri, female
breast and prostate cancer, the incidence rates of which differ
from elsewhere in West Africa, all the other common cancers
studied here had similar rates of occurrence. Specifically, the
corresponding ASR(W)s of liver, lung plus bronchus and NHL
were comparable to elsewhere in West Africa [7]. This may be
suggesting that the inherent under-ascertainment of cancer
cases via population-based cancer registration may not be
adversely different in West Africa.
Conclusions
To our knowledge, we have conducted one of the longest
assessments of cancer incidence in sub-Saharan Africa based
on continuous population-based cancer registration covering
an indigenous African population largely in rural dwelling.
Current reviews of cancer in Africa show cervix, breast, and
HIV-associated Kaposi’s sarcoma as the most common
malignancies among indigenous Africans. In male Africans, the
currently reported top five cancers were: Kaposi’s sarcoma
(KS) (forming 13% of all cancers in males) and cancer of the
liver (15%), prostate (10%), bladder (6%), and NHL (6%), while
in their female counterparts these were, cervix cancer (which
makes up 23% of all cancers in females), breast cancer (19%),
Kaposi’s sarcoma (5%), liver cancer (5%) and NHL (4%) (See
reference [11]). Our current analysis includes all of the above
top five cancers but KS and bladder. In contrast, we show that
in The Gambia, lung plus bronchus and stomach cancers are
also among the top five. Such observations are indications that
there are inherent differences in the cancer profile between the
various populations and or regions of the continent. There is
therefore the need to elucidate these differences in order to
assist the formulation and or adaptation of appropriate cancer
control policies to suite the various populations of the continent.
The current series from The Gambia adds information to the
existing knowledge of cancer incidence in sub-Saharan Africa.
In principle, the information adds clarity and precision to
designing, implementing and evaluating targeted interventions
aimed at reducing the burden of the most common cancers in
the continent and health improvement for the population.
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